SCHEMBL3175398

SCHEMBL3175398

CCOC(=O)CC(=O)c1ccccc1OCc1ccccc1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 2/20 0.48
NPC1 O15118 1/20 0.48
CYP1A2 P05177 1/20 0.48
POLB P06746 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
PLA2G1B P04054 1/20 0.47
ATG4B Q9Y4P1 1/20 0.47
MAPT P10636 3/20 0.47
IDO1 P14902 1/20 0.46
TDO2 P48775 1/20 0.46
HPGD P15428 1/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
KMT2A Q03164 1/20 0.46
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
TSHR P16473 1/20 0.44
PARP14 Q460N5 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30218361 0.86 NPC1 (0.62) ABCB1NPC1POLBMAPTIDO1
SCHEMBL954173 0.86 NPC1 (0.62) ABCB1NPC1POLBMAPTIDO1
SCHEMBL11339085 0.83 HCRTR1 (0.58) ABCB1NPC1MAPTHPGDKDM4E
SCHEMBL377080 0.83 ABCB1 (0.61) ABCB1NPC1MAPTMEN1ALDH1A1
SCHEMBL3178001 0.82 ABCB1 (0.52) ABCB1NPC1POLBPLA2G1BATG4B
SCHEMBL9518005 0.80 SGMS2 (0.54) NPC1MAPTIDO1TDO2MEN1
SCHEMBL4431174 0.80 ABCB1 (0.51) ABCB1NPC1POLBMAPTIDO1
SCHEMBL3179257 0.80 ABCB1 (0.52) ABCB1NPC1POLBMAPTHPGD
SCHEMBL14936748 0.79 ABCB1 (0.52) ABCB1NPC1MAPTKDM4EMEN1
SCHEMBL3947925 0.78 MEN1 (0.52) NPC1POLBMAPTIDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645772-B2 4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid; Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis WELLSTAT THERAPEUTICS CORPORATION (US) 2010-01-12 US claimed
US-20060035970-A1 Compounds for the treatment of metabolic disorders WELLSTAT THERAPEUTICS CORPORATION 2006-02-16 US claimed
EP-1556085-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Wellstat Therapeutics Corporation (US) 2005-07-27 EP claimed
WO-2004041165-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2004-05-21 WO claimed
US-7645772-B2 4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid; Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis WELLSTAT THERAPEUTICS CORPORATION (US) 2010-01-12 US disclosed
US-20060035970-A1 Compounds for the treatment of metabolic disorders WELLSTAT THERAPEUTICS CORPORATION 2006-02-16 US disclosed
EP-1556085-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Wellstat Therapeutics Corporation (US) 2005-07-27 EP disclosed
WO-2004041165-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2004-05-21 WO disclosed